zolbetuximab
astellas
[]
#gi23 gave the highly anticipated presentation of folfox +/- zolbetuximab for claudin 18.2 gastric/gej jxn ca ~3 mo in mos, achieving an 18.2 month mos - the longest ever in a study to the investigators for changing the standard of care 
GI Onc at Hopkins, focusing on #PancreaticCancer, #PrecisionMedicine. Striving to improve patient outcomes.
Originator of #TumorBoardTuesday @TumorBoardTues